Abstract
Among the Retinoic Acid (RA) derivatives, retinamides, and in particular N-(4-hydroxyphenyl) retinamide (4-HPR), are currently being investigated in selected cases of cancer chemoprevention. The cellular target range, however, seems to be limited, as cells of hemopoietic origin are virtually incapable of terminal differentiation upon addition of the compound. We have reconsidered the effect of 4-HPR on HL-60 cells by taking advantage of a mutant clone, generated in our laboratory, unresponsive to RA but highly responsive to dimethylsulfoxide (DMSO). We show here that this clone, upon addition of 4-HPR, although unable of undergoing full differentiation, shows considerable reduction of clonal growth. Moreover, the combination of 4-HPR and RA resulted in a much greater effect than the administration of 4-HPR alone. We suggest that 4-HPR and RA, at least in terms of mediating growth inhibition, may follow different metabolic pathways.
| Original language | English |
|---|---|
| Pages (from-to) | 175-180 |
| Number of pages | 6 |
| Journal | Leukemia and Lymphoma |
| Volume | 17 |
| Issue number | 1-2 |
| DOIs | |
| Publication status | Published - 1995 |
Fingerprint
Keywords
- CD16
- CDIIb
- CDlO
- Fenretinide
- Retinoic acid
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
A retinoic acid resistant HL-60 cell clone sensitive to n-(4-hydroxyphenyl) retinamide-mediated clonal growth inhibition. / Brigati, Claudio; Ferrari, Nicoletta; Megna, Mauro; Roncella, Silvio; Cutrona, Giovanna; Tosetti, Francesca; Vidali, Giorgio.
In: Leukemia and Lymphoma, Vol. 17, No. 1-2, 1995, p. 175-180.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A retinoic acid resistant HL-60 cell clone sensitive to n-(4-hydroxyphenyl) retinamide-mediated clonal growth inhibition
AU - Brigati, Claudio
AU - Ferrari, Nicoletta
AU - Megna, Mauro
AU - Roncella, Silvio
AU - Cutrona, Giovanna
AU - Tosetti, Francesca
AU - Vidali, Giorgio
PY - 1995
Y1 - 1995
N2 - Among the Retinoic Acid (RA) derivatives, retinamides, and in particular N-(4-hydroxyphenyl) retinamide (4-HPR), are currently being investigated in selected cases of cancer chemoprevention. The cellular target range, however, seems to be limited, as cells of hemopoietic origin are virtually incapable of terminal differentiation upon addition of the compound. We have reconsidered the effect of 4-HPR on HL-60 cells by taking advantage of a mutant clone, generated in our laboratory, unresponsive to RA but highly responsive to dimethylsulfoxide (DMSO). We show here that this clone, upon addition of 4-HPR, although unable of undergoing full differentiation, shows considerable reduction of clonal growth. Moreover, the combination of 4-HPR and RA resulted in a much greater effect than the administration of 4-HPR alone. We suggest that 4-HPR and RA, at least in terms of mediating growth inhibition, may follow different metabolic pathways.
AB - Among the Retinoic Acid (RA) derivatives, retinamides, and in particular N-(4-hydroxyphenyl) retinamide (4-HPR), are currently being investigated in selected cases of cancer chemoprevention. The cellular target range, however, seems to be limited, as cells of hemopoietic origin are virtually incapable of terminal differentiation upon addition of the compound. We have reconsidered the effect of 4-HPR on HL-60 cells by taking advantage of a mutant clone, generated in our laboratory, unresponsive to RA but highly responsive to dimethylsulfoxide (DMSO). We show here that this clone, upon addition of 4-HPR, although unable of undergoing full differentiation, shows considerable reduction of clonal growth. Moreover, the combination of 4-HPR and RA resulted in a much greater effect than the administration of 4-HPR alone. We suggest that 4-HPR and RA, at least in terms of mediating growth inhibition, may follow different metabolic pathways.
KW - CD16
KW - CDIIb
KW - CDlO
KW - Fenretinide
KW - Retinoic acid
UR - http://www.scopus.com/inward/record.url?scp=0028901510&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028901510&partnerID=8YFLogxK
U2 - 10.3109/10428199509051719
DO - 10.3109/10428199509051719
M3 - Article
VL - 17
SP - 175
EP - 180
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 1-2
ER -